Implementation of systematic screening for anxiety, disability and pain in children aged 8 to 18 years presenting with abdominal pain at a gastroenterology division of a large medical center resulted in an increase in screening rates and psychological referrals.
A 2-week course of treatment with rifaximin for diarrhea-predominant irritable bowel syndrome was found to improve abdominal pain symptoms.
Similar reductions were seen for most bothersome symptom severity for all treatment groups over 12 weeks (estradiol, −1.4; moisturizer, −1.2; and placebo, −1.3).
Trigger point injection with steroids and pulsed radiofrequency treatment of trigger points may effectively relieve pain associated with abdominal myofascial pain syndrome.
Lumbopelvic pain in well-functioning older adults was found to be associated with greater walking-related energy expenditure and reduced walking endurance compared with individuals without lumbopelvic pain.
Lateral Cutaneous Nerve Entrapment Syndrome, a newly defined syndrome characterized by flank tenderness, may successfully be treated with lidocaine injections and alternative treatments.
Public-private partnership initiative develops core diagnostic criteria for abdominal, pelvic, and urogenital pain associated with irritable bowel syndrome.
Treatment with elagolix was associated with sustained reduction in average monthly dysmenorrhea and non-menstrual pelvic pain through a 12-month treatment period.
A flexible extended regimen of 20 mg ethinylestradiol and 3 mg drospirenone (FlexibleMIB) was shown to be superior to placebo for reducing endometriosis-related pain.
Long-term exposure to progestin-only oral contraceptives or to a progestin intrauterine device is associated with a small beneficial effect on pelvic girdle pain.